α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Tumors are fibrotic and characterized by abundant, remodeled, and cross-linked collagen that stiffens the extracellular matrix stroma. The stiffened collagenous stroma fosters malignant transformation of the tissue by increasing tumor cell tension to promote focal adhesion formation and potentiate growth factor receptor signaling through kinase. Importantly, collagen cross-linking requires fibronectin (FN). Fibrotic tumors contain abundant FN, and tumor cells frequently up-regulate the FN receptor α5β1 integrin. Using transgenic and xenograft models and tunable two- and three-dimensional substrates, we show that FN-bound α5β1 integrin promotes tension-dependent malignant transformation through engagement of the synergy site that enhances integrin adhesion force. We determined that ligation of the synergy site of FN permits tumor cells to engage a zyxin-stabilized, vinculin-linked scaffold that facilitates nucleation of phosphatidylinositol (3,4,5)-triphosphate at the plasma membrane to enhance phosphoinositide 3-kinase (PI3K)-dependent tumor cell invasion. The data explain why rigid collagen fibrils potentiate PI3K activation to promote malignancy and offer a perspective regarding the consistent up-regulation of α5β1 integrin and FN in many tumors and their correlation with cancer aggression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · cited 1×
“Accordingly, an assortment of pharmacological inhibitors have been developed to target these kinases and their associated signaling molecules to treat various solid cancers with various degrees of clinical success (McCubrey et al., 2008; Engelman, 2009; Wong et al., 2010; Thorpe et al., 2015).”
BackgroundHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222 · cited 2×
“…corrupted tissues with high interstitial pressure, elevated compression, increased solid stress, ECM stiffening, and increased cellular tension (Heldin et al., 2004; Paszek et al., 2005; Levental et al., 2009; Lopez et al., 2011; Samuel et al., 2011; Provenzano et al., 2012; Mouw et al., 2014;…”
BackgroundProvenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 4×
“Moreover, reducing cell tension or interstitial pressure or preventing matrix stiffening by inhibiting collagen cross-linking decreases tumor incidence and aggression and can improve treatment efficacy (Paszek et al., 2005; Levental et al., 2009; Samuel et al., 2011; Provenzano et al., 2012; Chauhan et al., 2013; Mill…”
BackgroundInfluentialPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483 · cited 11×
“HMT3522 S1 nonmalignant MECs (which express negligible α5 integrin) were engineered to express either a tetracycline (Tet)-regulated enhanced green fluorescent protein (eGFP)-tagged α5 integrin or an eGFP-tagged α2 integrin.”
BackgroundMethodInfluentialSelf-citationCalvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
FAK in cancer: mechanistic findings and clinical applications
Sulzmaier, F. J., Jean, C., & Schlaepfer, D. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3792 · Cited by 1,381 · cited 1×
“Elevated β1-integrin levels and focal adhesion kinase (FAK) activity correlate positively with high tumor grade and predict for poor patient prognosis (Recher et al., 2004; dos Santos et al., 2012; Sulzmaier et al., 2014).”
BackgroundChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 2×
“Moreover, reducing cell tension or interstitial pressure or preventing matrix stiffening by inhibiting collagen cross-linking decreases tumor incidence and aggression and can improve treatment efficacy (Paszek et al., 2005; Levental et al., 2009; Samuel et al., 2011; Provenzano et al., 2012; Chauhan et al., 2013; Mill…”
BackgroundStephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“EGFR signaling enhances MEC growth and survival by activating PI3K and extracellular signal–regulated kinase (ERK) (Zahir et al., 2003; Yuan and Cantley, 2008), and oncogenic transformation requires PI3K and ERK signaling (Turner and Grose, 2010; Kandoth et al., 2013; Stephen et al., 2014).”
BackgroundWang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Self-citationHirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593
LOX-Mediated Collagen Crosslinking Is Responsible for Fibrosis-Enhanced Metastasis
Cox, T. R., Bird, D., Baker, A.-M., Barker, H. E., Ho, M. W.-Y., Lang, G., & Erler, J. T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2233 · Cited by 571 · cited 2×
“Volume 28 November 1, 2017 FN-bound α5β1 tension drives malignancy | 2959 (Kubow et al., 2009; Cox et al., 2013).”
BackgroundTargeting the PI3K signaling pathway in cancer
Wong, K.-K., Engelman, J. A., & Cantley, L. C. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.002 · Cited by 543
ROCK and JAK1 Signaling Cooperate to Control Actomyosin Contractility in Tumor Cells and Stroma
Sanz-Moreno, V., Gaggioli, C., Yeo, M., Albrengues, J., Wallberg, F., Viros, A., Hooper, S., Mitter, R., Féral, C. C., Cook, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.018 · Cited by 409 · cited 1×
“…suggest that combinatorial treatments that target both the mechanical properties of the cell or tissue and specific oncogenic signaling pathways might prove to be a better therapeutic option (Sanz-Moreno et al., 2011; Calvo et al., 2013; Sadok et al., 2015; Jiang et al., 2016; Laklai et al., 2016).”
BackgroundThe Evolution of Extracellular Matrix
Özbek, S., Balasubramanian, P. G., Chiquet-Ehrismann, R., Tucker, R. P., & Adams, J. C. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-03-0251 · Cited by 347 · cited 1×
“To explore the possibility of a relationship between FN and the malignant phenotype of MECs, we conducted reconstituted basement Desgrosellier and Cheresh, 2010; Nam et al., 2010; Ozbek et al., 2010; Gehler et al., 2013; Pickup et al., 2014; Theocharis et al., 2015).”
MethodPark, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3071 · Cited by 326 · cited 2×
“…levels, migrate faster and contract collagenous matrices to a greater extent (Mierke et al., 2011), and studies showing that blocking the activity of RGD-binding receptors is critical for expression of the malignant phenotype of cultured breast cancer cells (Park et al., 2006; Nam et al., 2010).”
BackgroundNam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196 · cited 7×
“…levels, migrate faster and contract collagenous matrices to a greater extent (Mierke et al., 2011), and studies showing that blocking the activity of RGD-binding receptors is critical for expression of the malignant phenotype of cultured breast cancer cells (Park et al., 2006; Nam et al., 2010).”
BackgroundMethodInfluentialMiroshnikova, Y. A., Jorgens, D. M., Spirio, L., Auer, M., Sarang-Sieminski, A. L., & Weaver, V. M. (2011) · Physical Biology · doi:10.1088/1478-3975/8/2/026013 · Cited by 82 · cited 1×
“…Carey et al., 2012), and a stiffened collagen ECM can promote malignant transformation in culture (Paszek and Weaver, 2004; Levental et al., 2009; Miroshnikova et al., 2011; Cassereau et al., 2015), the major collagen receptor, α2β1 integrin, inhibits rather than promotes malignancy in vivo…”
BackgroundSelf-citation
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
“When cancer cells encountered stiff collagen fibers at fibronectin-rich invasive fronts, they engaged αvβ1 integrin to recruit vinculin and zyxin to focal adhesions sites in a tension-dependent manner to induce PI3K signaling [153].”
BackgroundThe Extracellular Matrix Modulates the Metastatic Journey
Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 537
Self-citationMechanotransduction in tumor progression: The dark side of the force
Broders-Bondon, F., Nguyen Ho-Bouldoires, T. H., Fernandez-Sanchez, M.-E., & Farge, E. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201701039 · Cited by 319
“…signaling (Paszek et al., 2005; Mitra and Schlaepfer, 2006; Friedland et al., 2009; Levental et al., 2009; Samuel et al., 2011; Leight et al., 2012; Miroshnikova et al., 2017) and to inhibit apoptosis in a TGF-β1–dependent process, all features positively involved in tumor growth (Hadjipanayi et…”
BackgroundTargeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Metadata
- Authors
- Miroshnikova, Y. A., Rozenberg, G. I., Cassereau, L., Pickup, M., Mouw, J. K., Ou, G., Templeman, K. L., Hannachi, E.-I., Gooch, K. J., Sarang-Sieminski, A. L., García, A. J., & Weaver, V. M.
- Venue
- Molecular Biology of the Cell
- Published
- 2017-11
- Volume
- 28
- Issue
- 22
- Pages
- 2958-2977
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2751895094
- Cited by
- 74
- References
- 21
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.